About six woody species, based on their commercial importance, were chosen for this project, and the respective secondary metabolites are targeted for production and commercialization.
“The main objective of the current research is to avoid exploitation of trees for extraction of actives, but alternatively produce them by in vitro techniques in the lab followed by scale up at pilot level for evaluation of commercial feasibility,” said Sami-Sabinsa Group founder Dr. Muhammed Majeed. “Sami Labs has state-of-the-art laboratory set up with sophisticated analytical instruments for identification, characterization and quantification of the bio-active secondary metabolites.”
Sami Labs is setting up a pilot scale facility in this regard, that will have perfusion bioreactors in a classified area with downstream processing of the extracts and purification of the actives. The scientists involved are highly confident to commercialize the products accessible through this novel route.